MENA 2024 Recordings-Type 1 Diabetes Management Across the World

Video Transcription

Video Summary

The speaker, delivering a presentation on their birthday, discussed the management of type 1 diabetes (referred to as "typhoid diabetes") globally, highlighting its rising prevalence and varied regional impacts. The highest projected increases in prevalence by 2040 are noted in Sub-Saharan Africa and the MENA region. Traditionally seen as a juvenile disease, type 1 diabetes now affects all ages, often misdiagnosed as type 2 due to overlapping symptoms.<br /><br />Type 1 diabetes progresses through four stages: genetic susceptibility, impaired glucose tolerance with antibody presence, clinical symptoms, and insulin dependency. Efforts to slow its progression or find a cure have been largely unsuccessful, though recent strategies are more promising.<br /><br />The presentation emphasized the critical role of early antibody screening, which can prevent severe complications and facilitate early treatment or trial inclusion. Teplizumab, an anti-CD3 antibody, has shown promise in delaying the onset of type 1 diabetes by about two years in high-risk individuals.<br /><br />The speaker highlighted the importance of diabetes technology, such as continuous glucose monitors (CGMs) and automated insulin delivery (AID) systems, in improving glycemic control. However, disparities in access and use, particularly due to socio-economic and healthcare system differences, pose significant challenges worldwide. The talk concluded with a call for equitable access to diabetes care and technology as a basic right.

Asset Subtitle

Dr. Halis Akturk

Keywords

type 1 diabetes

global prevalence

Sub-Saharan Africa

MENA region

antibody screening

Teplizumab

diabetes technology

equitable access